Am J Transplant, Volume 3, Suppl 5 Archives - Page 140 of 178 - ATC Abstracts

2013 American Transplant Congress
Early Complications after ABO Incompatible Kidney Transplantation: A National Database Study
K. Lentine, D. Axelrod, C. Simpkins, H. Xiao, J. Tuttle-Newhall, M. Schnitzler, V. Dharnidharka, D. Brennan, D. Segev
Saint Louis Univ; Dartmouth Univ; Johns Hopkins Univ, ; Washington Univ
ABO incompatible (ABOi) live donor kidney transplantation (LKDT) with plasmapheresis can achieve acceptable graft survival. However, intermediate outcomes after ABOi LDKT have not been described…
2013 American Transplant Congress
Family Experiences and Perspectives on Deceased Organ and Tissue Donation for Transplantation
A. Ralph, J. Chapman, J. Craig, J. Gillis, M. Irving, A. Tong
Sydney School of Public Health, The University of Sydney, Sydney, NSW, Australia; Centre for Kidney Research, The Children's Hospital at Westmead, Sydney, NSW, Australia; Centre for Transplant and Renal Research, Westmead Hospital, Sydney, NSW, Australia; Centre for Values, Ethics and Law in Medicine, The University of Sydney, Sydney, NSW, Australia
Background: A contributing factor to the shortage of deceased organ donors is family refusal to give consent, or veto a prior decision of the donor.…
2013 American Transplant Congress
Prospective and Randomized Trial Comparing Tacrolimus Versus Sirolimus after Simultaneous Pancreas-Kidney Transplantation
D. Cantarovich, E. Papuchon, G. Blancho, J. Dantal, M. Giral, J. Branchereau, G. Karam
Institut de Transplantation-Urologie-Néphrologie, Nantes University Hospital, Nantes, France
Introduction. Minimizing or sparing potentially nephrotoxic and diabetogenic immunosuppressants could represent an advantage following simultaneous pancreas-kidney transplantation (SPK-Tx).Purpose. We report here the actual one-year result…
2013 American Transplant Congress
Variability of IMPDH-Activity in Long-Term MPA Mediated Immunosuppression
D. Abendroth, M. Marzinzig, M. Stangl
Center of Surgery, University of Ulm, Ulm, Germany; Visceral and Transplant Surgery, Ludwig-Maximilians-Universität, Munich, Germany
Purpose of this study was to examine wether the long term exposure for mycophenolate mofetil (MMF) or enteric coated form (EC-MPS) is leading to an…
2013 American Transplant Congress
Comparison of Transumbilical and Conventional Laparoscopic Donor Nephrectomy
M. Minz, V. Kaji, A. Sharma, S. Singh, D. Kenwar
Department of Renal Transplant Surgery, Post Graduate Institute of Medical Education and Research, Chandigarh, India
Forty-eight healthy voluntary renal donors between 18 and 60 years of age with BMI less than 30 who were planned for laparoscopic left side donor…
2013 American Transplant Congress
Liver Transplantation: Do Senescence and Autophagy Modulate the Development of Chronic Pathology
J. Brain, E. Thompson, D. Jones, A. Burt, J. Kirby
ICM, Newcastle University, Newcastle upon Tyne, United Kingdom; Clinical Deanery, Newcastle University, Newcastle uon Tyne, United Kingdom
During the past 20 years there has been a reduction in the incidence of both acute cellular rejection (ACR) and chronic ductopenic rejection following liver…
2013 American Transplant Congress
Efficacy of Everolimus with Reduced Cyclosporine in Japanese De Novo Renal Transplant Recipients: 24-Month, Randomized, Multicenter Study
K. Saito, K. Uchida, S. Takahara, N. Yoshimura, S. Teraoka, C. Cornu-Artis, E. Kobayashi, K. Takahashi
Niigata University, Niigata, Japan; Aichi Medical University, Aichi, Japan; Osaka University, Osaka, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; International University of Health and Welfare, Atami Hospital, Shizouka, Japan; Novartis Pharma AG, Basel, Switzerland; Jichi Medical University, Tochigi, Japan
Introduction: Results from study A1202 showed that everolimus (EVR) plus reduced dose cyclosporine (rCsA) prevents acute rejection, preserves renal function, and reduces incidence of viral…
2013 American Transplant Congress
Positive Flow Crossmatches in Renal Patients without “Detectable” Anti-Donor HLA Antibodies; Maximizing Renal Transplant Rate by Decreasing False Positive Crossmatches
R. Cirocco, J. Mendiolina, L. Biondi, M. Moritz
HLA Laboratory and the Transplant Center, Lehigh Valley Health Network, Allentown, PA
A recurring problem in recipient selection for deceased donor renal transplantation is a positive crossmatch in a “non-donor antigen sensitized “individuals. We initiated a study…
2013 American Transplant Congress
IL-33: Friend or Foe?
D. Abendroth, M. Marzinzig, M. Stangl
Center of Surgery, University of Ulm, Ulm, Germany; Visceral and Transplant Surgery, Ludwig-Maximilians-University, Munich, Germany
Introduction We hypothesize that innate inflammatory response either preexistent in the recipient or released by injured allografts during transplantation may influence graft outcome. In a…
2013 American Transplant Congress
Effects of Everolimus and Tacrolimus Exposure on Efficacy and Renal Function in Liver Transplant Recipients at 24 Months in a Randomized Trial (H2304)
L. Fischer, G. Kaiser, B. Koneru, L. Toselli, F. Durand, N. Heaton, K. Shetty, G. Dong, P. Lopez, G. Junge, J. Kovarik
For the H2304 Study Group, Hamburg, Germany; Novartis Pharma AG, Basel, Switzerland
Purpose: The present analysis aims to explore the effect of everolimus (EVR) and tacrolimus (TAC) exposure on efficacy and safety events of interest in de…